$ARGX

AI Analysis

Generated on May 11, 2026

AI Score
72/ 100
Hold$ARGX

argenx SE

$ARGXNASDAQHealthcareLarge-Cap

argenx develops antibody-based therapies for autoimmune diseases with lead product Vyvgart for myasthenia gravis.

Market Cap
$32.0B
Revenue (TTM)
$2.5B
+85.0%
Net Income (TTM)
$0.2B
N/A
EPS (TTM)
$3.50
P/E Ratio
N/A
Dividend Yield
0.0%
52-Week Range
$350-$630
Beta
0.72
Dimension Scores
Fundamental
62
Technical
68
Sentiment
78
Risk / Reward
60
Momentum
82
FundTechSentRiskMome
Financial Health
Profitability
67moderate
Growth
85strong
Liquidity
68strong
Solvency
64strong
Efficiency
60moderate

Valuation, technical analysis, investment thesis, risk assessment and more for $ARGX

Free · No credit card required

Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.

Explore more

Analyze any stock with AI

Get a structured equity research report covering fundamentals, technicals, sentiment, risk, and investment thesis — in about 60 seconds.